Skip to main content Skip to section navigation Skip to footer
OS Therapies, Inc.
  • About Us
  • Leadership
  • Technology
  • Angels
  • Trials
  • Investors
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Dec 24, 2024 9:32 am EST

OS Therapies Announces Pricing of $6 Million Private Placement

Nov 15, 2024 9:47 am EST

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 04, 2024 7:00 am EST

OS Therapies to Present at The Spartan Capital Investor Conference

Oct 30, 2024 8:51 am EDT

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

Oct 28, 2024 4:44 pm EDT

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Oct 24, 2024 8:46 am EDT

OS Therapies to Present at the LD Micro Main Event XVII

Oct 17, 2024 9:22 am EDT

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 03, 2024 8:00 am EDT

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

Sep 13, 2024 8:09 am EDT

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

Sep 11, 2024 8:15 am EDT

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
OS Therapies, Inc.
©2026 OS Therapies, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap